Results 301 to 310 of about 914,658 (345)
Some of the next articles are maybe not open access.
2022
This chapter provides an overview of the general principles and miscellaneous topics of clinical pharmacology that are relevant to pain medicine. This involves the World Health Organization (WHO) analgesic ladder which is mainly used for acute and cancer pain.
Sabina Bachtold +6 more
openaire +1 more source
This chapter provides an overview of the general principles and miscellaneous topics of clinical pharmacology that are relevant to pain medicine. This involves the World Health Organization (WHO) analgesic ladder which is mainly used for acute and cancer pain.
Sabina Bachtold +6 more
openaire +1 more source
Rapacuronium: clinical pharmacology
European Journal of Anaesthesiology, 2001The need for a rapid-acting non-depolarizing neuromuscular blocking agent with a short duration of action resulted in the synthesis of rapacuronium. The onset of maximum block with rapacuronium occurs in 60-90 s with doses of 1.5-2.5 mg kg-1 with a duration of clinical relaxation of 15-30 min.
R K, Mirakhur, K C, McCourt
openaire +2 more sources
Omapatrilat: Clinical pharmacology
Drugs of Today, 2000Omapatrilat is the most clinically advanced member of a new class of cardiovascular agents known as vasopeptidase inhibitors. Omapatrilat acts by inhibiting two key enzymes responsible for blood pressure regulation: neutral endopeptidase and angiotensin-converting enzyme.
openaire +2 more sources
Clinical pharmacology: Foscarnet
The American Journal of Medicine, 1992Foscarnet exerts its antiviral effects via reversible inhibition of viral polymerases. Pharmacodynamic data indicate that herpesvirus and human immunodeficiency virus replication is inhibited by therapeutically achievable concentrations of foscarnet; however, the concentrations of foscarnet required for such inhibition have been found to vary widely ...
openaire +2 more sources
Clinical Pharmacology Of Caffeine
Annual Review of Medicine, 1990Caffeine is the most widely consumed stimulant drug in the world. This chapter reviews the human pharmacology of caffeine; the evidence for its role in causing human disease, including addiction; and its potential usefulness as a therapeutic agent.
openaire +2 more sources
CLINICAL PHARMACOLOGY OF BENZODIAZEPINES
Annual Review of Medicine, 1987The benzodiazepines are the most widely used anxiolytic drugs. Their pharmacokinetic properties differ widely. Side effects are usually mild but dependence can supervene after long-term administration, even if normal therapeutic doses are not exceeded. Careful monitoring of use is essential.
openaire +2 more sources
Pharmacology and Clinical Pharmacology of Vigabatrin
Journal of Child Neurology, 1991Vigabatrin is an enzyme-activated, irreversible inhibitor of γ-aminobutyric acid (GABA) aminotransferase, which causes a marked increase in cerebral GABA concentration and a resulting anticonvulsant action. Recovery from its effects requires the synthesis of new enzyme, and this may take several days following a single dose.
openaire +2 more sources
Clinical pharmacology overview
2012Abstract The first chapter of the book provides an introduction to pharmacology and its implementation in clinical practice.
openaire +1 more source